In addressing limitations of existing treatments for EGFR‐mutated NSCLC, mobocertinib (TAK‐788), a new irreversible EGFR TKI, was developed specifically to inhibit cancerous variants with activating EGFRex20ins mutations while maintaining selectivity for wild‐type EGFR.124. This evidence concerns the gene EGFR and non-small cell lung carcinoma.